NASDAQ:LJPCLa Jolla Pharmaceutical Stock Price, Forecast & News

La Jolla Pharmaceutical's stock was trading at $4.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LJPC shares have increased by 49.9% and is now trading at $7.21. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for La Jolla Pharmaceutical.

La Jolla Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for La Jolla Pharmaceutical.

La Jolla Pharmaceutical (NASDAQ:LJPC) released its earnings results on Monday, May, 4th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.60. The biopharmaceutical company had revenue of $7.59 million for the quarter, compared to analyst estimates of $8.50 million. View La Jolla Pharmaceutical's earnings history.

3 brokers have issued 1 year price targets for La Jolla Pharmaceutical's shares. Their forecasts range from $19.00 to $20.00. On average, they expect La Jolla Pharmaceutical's share price to reach $19.50 in the next twelve months. This suggests a possible upside of 170.5% from the stock's current price. View analysts' price targets for La Jolla Pharmaceutical.

Media coverage about LJPC stock has trended positive this week, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. La Jolla Pharmaceutical earned a daily sentiment score of 2.4 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock's share price in the near term. View the latest news aboutLa Jolla Pharmaceutical.

La Jolla Pharmaceutical saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 2,830,000 shares, an increase of 11.9% from the March 31st total of 2,530,000 shares. Based on an average daily volume of 828,300 shares, the days-to-cover ratio is presently 3.4 days. Currently, 11.0% of the company's shares are short sold. View La Jolla Pharmaceutical's Current Options Chain.

Some companies that are related to La Jolla Pharmaceutical include BAVARIAN NORDIC/S (BVNRY), Replimune Group (REPL), Adaptimmune Therapeutics (ADAP), Aerie Pharmaceuticals (AERI), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Vericel (VCEL), AVITA MED LTD/S (RCEL), Avrobio (AVRO), Prevail Therapeutics (PRVL), Oyster Point Pharma (OYST), Aptose Biosciences (APTO), MeiraGTx (MGTX), Harpoon Therapeutics (HARP) and Innate Pharma (IPHYF). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), Intercept Pharmaceuticals (ICPT), El Pollo LoCo (LOCO), Sarepta Therapeutics (SRPT), Neurocrine Biosciences (NBIX), Exelixis (EXEL), XOMA (XOMA), Juno Therapeutics (JUNO), Advanced Micro Devices (AMD) and Inovio Pharmaceuticals (INO).

La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."

La Jolla Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional investors include Tang Capital Management LLC (29.60%), BlackRock Inc. (5.70%), Morgan Stanley (2.34%), State Street Corp (1.50%), Geode Capital Management LLC (1.15%) and First Midwest Bank Trust Division (0.48%). Company insiders that own La Jolla Pharmaceutical stock include Darryl Wellinghoff, George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla and Life Sciences Maste Perceptive. View institutional ownership trends for La Jolla Pharmaceutical.

LJPC stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Geode Capital Management LLC, BlackRock Inc., State Street Corp, JPMorgan Chase & Co., Acadian Asset Management LLC, Parametric Portfolio Associates LLC, and UBS Group AG. View insider buying and selling activity for La Jolla Pharmaceutical.

LJPC stock was acquired by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Morgan Stanley, First Midwest Bank Trust Division, Two Sigma Investments LP, Premier Asset Management LLC, Engineers Gate Manager LP, Deutsche Bank AG, and Advisor Group Holdings Inc.. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include Darryl Wellinghoff, George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, and Lakhmir S Chawla. View insider buying and selling activity for La Jolla Pharmaceutical.

Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LJPC stock can currently be purchased for approximately $7.21.

La Jolla Pharmaceutical has a market capitalization of $196.83 million and generates $23.05 million in revenue each year. The biopharmaceutical company earns $-116,510,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis. La Jolla Pharmaceutical employs 169 workers across the globe.

The official website for La Jolla Pharmaceutical is www.lajollapharmaceutical.com.

La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]